SECURITIESFORM AND EXCHANGE COMMISSION8-K

IfItem an9.01 emergingFinancial growthStatements company,and indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActExhibits. ☐

UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

~~WASHINGTON,~~CURRENT ~~D.C. 20549~~REPORT

~~FORM~~Pursuant ~~8-K~~to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~CURRENT~~Date ~~REPORT~~of Report (Date of earliest event reported): January 07, 2026

~~Pursuant~~EyePoint, ~~to Section 13 or 15(d)~~Inc.

(Exact name of ~~the~~Registrant ~~Securities~~as ~~Exchange~~Specified ~~Act~~in ofIts ~~1934~~Charter)

Date of Report (Date of earliest event reported): December 8, 2025


Delaware	000-51122	26-2774444
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

480 Pleasant Street
Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

~~EyePoint~~Registrant’s ~~Pharmaceuticals~~Telephone Number, ~~Inc.~~Including Area Code: (617) 926-5000

(~~Exact~~Former ~~name~~Name ofor ~~Registrant~~Former asAddress, ~~Specified~~if inChanged ~~Its~~Since ~~Charter~~Last Report)

Delaware		000-51122		26-2774444
(State or Other Jurisdictionof Incorporation)		(Commission File Number)		(IRS EmployerIdentification No.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

480 Pleasant Street
Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~Registrant’s~~☐Soliciting ~~Telephone~~material ~~Number,~~pursuant ~~Including~~to ~~Area~~Rule ~~Code:~~14a-12 under the Exchange Act (~~617)~~17 ~~926~~CFR 240.14a-~~5000~~12)

~~(Former~~☐Pre-commencement ~~Name~~communications orpursuant ~~Former~~to ~~Address,~~Rule if14d-2(b) ~~Changed~~under ~~Since~~the ~~Last~~Exchange ~~Report~~Act (17 CFR 240.14d-2(b))

~~Check the appropriate box below if the Form 8~~☐Pre-Kcommencement ~~filing~~communications ispursuant ~~intended~~ to ~~simultaneously~~Rule ~~satisfy~~13e-4(c) ~~the~~under ~~filing obligation of~~ the ~~registrant~~Exchange ~~under~~Act ~~any~~(17 ofCFR ~~the following provisions:~~240.13e-4(c))

☐Securities ~~Written~~registered ~~communications~~ pursuant to ~~Rule~~Section ~~425~~12(b) ~~under~~of the ~~Securities~~ Act ~~(17 CFR 230.425)~~:

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	EYPT	The Nasdaq Global Market

☐Indicate ~~Pre-commencement~~by ~~communications~~check ~~pursuant~~mark towhether the registrant is an emerging growth company as defined in Rule ~~14d-2~~405 of the Securities Act of 1933 (b§ 230.405 of this chapter) ~~under~~or Rule 12b-2 of the Securities Exchange Act ~~(17~~of ~~CFR~~1934 (§ 240.~~14d~~12b-2(b of this chapter)).

☐Emerging ~~Pre-commencement~~growth ~~communications~~company ~~pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~☐

~~Securities~~If ~~registered~~an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 12 13(ba) of the Exchange Act:. ☐

Title of each class		TradingSymbol(s)		Name of each exchangeon which registered
Common Stock, par value $0.001		EYPT		The Nasdaq Global Market

Item 2.02. Results of Operations and Financial Condition.

~~Indicate~~On byJanuary ~~check~~7, ~~mark~~2026, ~~whether~~EyePoint, Inc. (the ~~registrant~~“Company”) isissued ana ~~emerging~~press ~~growth~~release ~~company~~announcing asits ~~defined~~preliminary December 31, 2025 cash, and certain other corporate updates. The amounts included in ~~Rule~~the ~~405~~press release are preliminary, have not been audited and are subject to change upon completion of the ~~Securities~~Company’s ~~Act~~audited offinancial ~~1933~~statements ~~(§ 230~~for the year ended December 31, 2025.~~405~~ ofAdditional ~~this~~information ~~chapter)~~and ordisclosures ~~Rule~~would ~~12b-2~~be required for a more complete understanding of the ~~Securities~~Company’s ~~Exchange~~financial ~~Act~~position and results of ~~1934~~operations ~~(§ 240~~as of December 31, 2025.~~12b-2~~ A copy of ~~this~~the ~~chapter)~~press release is filed as Exhibit 99.1 hereto.

~~Emerging~~The ~~growth~~information ~~company ☐~~included under Item 2.02 of this current report on Form 8-K, including Exhibit 99.1, is deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and, therefore, may be incorporated by reference in filings under the Securities Act of 1933, as amended.

EyePoint Pharmaceuticals, Inc.

Date: December 8, 2025

/s/ George O. Elston

George O. Elston

Executive Vice President and Chief Financial Officer

~~Item~~(d) 5Exhibits.03 ~~Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.~~

On December 8, 2025, EyePoint, Inc. (the “Company”) filed a certificate of amendment (the “Certificate of Amendment”) to its Certificate of Incorporation, as amended, solely to change the Company’s name from “EyePoint Pharmaceuticals, Inc.” to “EyePoint, Inc.” The name change became effective on December 8, 2025. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.


Exhibit No.		Description
99.1		Press Release of EyePoint, Inc. dated January 7, 2026
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

In connection with the name change, the Company’s Board of Directors approved an amendment (the “By-laws Amendment”) to the Company’s by-laws, as amended (the “By-laws”), to reflect the change in the Company’s name, also effective December 8, 2025. No other changes were made to the By-laws. A copy of the By-laws Amendment is attached as Exhibit 3.2 hereto and is incorporated herein by reference. SIGNATURES

~~The~~Pursuant ~~Company’s~~to ~~common~~the ~~stock~~requirements ~~continues~~of tothe ~~trade~~Securities onExchange Act of 1934, the ~~Nasdaq~~registrant ~~Global~~has ~~Market~~duly ~~under~~caused this report to be signed on its behalf by the ~~ticker~~undersigned ~~symbol~~hereunto ~~“EYPT.”~~duly authorized.

The name change does not affect the rights of the Company’s security holders, and the CUSIP number for Company’s common stock will continue to be 30233G209.


			EYEPOINT, INC.

Date:	January 7, 2026	By:	/s/ George O. Elston
			George O. Elston Executive Vice President and Chief Financial Officer

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
3.1		Certificate of Amendment to Certificate of Incorporation.
3.2		Amendment No. 2 to the By-Laws.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Filing Compare · EyePoint, Inc.